Clinical Trials

70 enrolled

Stomach Neoplasms

NCT05636150 2022-12-05

A Phase II Clinical Study of Fruquintinib Combined With S-1 for Advanced Esophageal Squamous Cell Carcinoma

48 enrolled

Esophageal Squamous Cell Carcinoma

NCT05627414 2022-11-25

Conversion Therapy of Disitamab Vedotin Combined With Sintilimab and S-1 in HER2 Overexpression Gastric Cancer

Stomach Neoplasms

NCT05529355 2022-09-07

Effect and Safety of Envafolimab Combined With Endostar/S-1 in Second-line of Advanced Non-small Cell Lung Cancer

45 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03946969 2022-07-19

Sintilimab in Combination With Chemotherapy in Neoadjuvant Treatment of Potentially Resectable Esophageal Cancer

Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

NCT05441254 2022-07-08

Camrelizumab Combined With Intraperitoneal Infusion of Nab-paclitaxel, Intravenous Chemotherapy and S-1 in the Treatment of Advanced Gastric Cancer With Peritoneal Metastasis：Single-arm, Prospective Clinical Study

33 enrolled

Stage IV Gastric Cancer With Metastasis

NCT05218148 2022-04-06

SOX Combined With Sintilimab and Trastuzumab Versus SOX Regimen in the Perioperative Treatment of HER2-positive Locally Advanced Gastric Adenocarcinoma

GastrointestinalOther solid neoplasm

44 enrolled

HER2-positive

NCT04062058 2022-01-24

A Phase II Study of Total Neoadjuvant Therapy for Locally Advanced Gastric Cancer

82 enrolled

Stomach Neoplasms

NCT05204173 2022-01-24

Efficacy and Safety of Sintilimab Combined Intraperitoneal and Intravenous Paclitaxel Plus Oral S-1 in Gastric Cancer Patients With Peritoneal Metastasis

Stomach Neoplasms

NCT05138159 2021-11-30

A Study of Donafenib Plus S-1 in Treating Patients With Metastatic Pancreatic Cancer After Chemotherapy With Nab-paclitaxel Plus Gemcitabine Regimen

10 enrolled

Pancreatic Neoplasms

NCT05111444 2021-11-08

Camrelizumab Plus Pyrotinib Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

65 enrolled

Stomach Neoplasms

NCT04982939 2021-08-31

Peri-operative Sintilimab in Combination With SOX in Locally Advanced Gastric Cancer

210 enrolled

Stomach Neoplasms

NCT04781686 2021-05-17

Apatinib Plus Camrelizumab Combined With Docetaxel and S1 in First-line Treatment for Metastatic Gastric Cancer

35 enrolled

Metastatic Gastric Adenocarcinoma

NCT03403101 2021-04-09

The Combination Chemotherapy of SIRIOX as First- or Second-Line Chemotherapy for Pancreatic Cancer

65 enrolled

Carcinoma, Pancreatic Ductal

NCT04808687 2021-03-22

Neoadjuvant Nab-Paclitaxel and S-1 in Resectable Pancreatic Cancer

72 enrolled

Pancreatic Neoplasms

NCT03986294 2021-01-15

NAPAN

122 enrolled

Pancreatic Neoplasms

NCT03457337 2020-07-10

S-1 Plus Gefitinib Versus Gefitinib Monotherapy in Patients With EGFR-sensitive Mutation Advanced Non-squamous NSCLC

200 enrolled

Thoracic

Advanced NSCLC With EGFR Mutation

NCT04377048 2020-05-06

Nivolumab Adding on Gemcitabine/S-1 in Metastatic Pancreatic Cancer

38 enrolled

Pancreatic Neoplasms

NCT04367025 2020-04-29

Efficacy and Safety of Perioperative Chemotherapy Plus PD-1 Antibody in Gastric Cancer

70 enrolled

Stomach Neoplasms

NCT04152889 2020-04-20

A Study to Evaluate Camrelizumab in Combination With Docetaxel +S-1 as Adjuvant Treatment Therapy in Stage III Gastric Cancer

20 enrolled

Stomach Neoplasms

NCT03397199 2020-04-15

Study of Apatinib Plus S-1 as the Therapy of Advanced Colorectal Cancer

120 enrolled

Colorectal Neoplasms

NCT03850769 2020-03-10

Neoadjuvant Nab-Paclitaxel and S-1 in Borderline Resectable Pancreatic Cancer

60 enrolled

Borderline Resectable Pancreatic Cancer

NCT03885219 2020-03-10

Nab-paclitaxel and S-1 in Patients With Locally Advanced Pancreatic Cancer

60 enrolled

Locally Advanced Pancreatic Cancer

NCT04258657 2020-02-06

Neoadjuvant Chomotherapy With Paclitaxel-albumin and S-1 for Advanced Gastric Cancer

20 enrolled

Stomach Neoplasms

NCT04101929 2019-11-05

Apatinib, Irinotecan and S-1 (ApaIRIS) in Treating Patients With Metastatic Pancreatic Cancer After AG Regimen

126 enrolled

Pancreatic Neoplasms

NCT04027764 2019-07-22

Toripalimab Combined With S1 and Albumin Paclitaxel in Patients With Advanced Biliary Tract Cancer

Advanced Biliary Tract Cancer

NCT03263741 2019-07-08

Exploratory Study on the Paclitaxel + S-1 + Oxaliplatin (PSOX) for Locally Advanced or Advanced Gastric Cancer

20 enrolled

Stomach Neoplasms

NCT03779464 2019-07-08

Study of Gemcitabine Plus Nab-paclitaxel Versus S1 Plus Nab-paclitaxel in Metastatic Adenocarcinoma of the Pancreas

132 enrolled

Pancreatic Neoplasms

NCT03990103 2019-06-19

S1+ Paclitaxel (IV&IP) + Bevacizumab (IP) Versus S1+Oxaliplatin as First-line Treatment in Gastric Cancer With Malignant Ascites

66 enrolled

Stomach Neoplasms

NCT03950141 2019-05-15

Apatinib Combined With S-1 as Maintenance Therapy for HER-2 Negatived Gastric Cancer

HER-2 Negatived Gastric Cancer

NCT01821248 2019-02-21

A Phase II Trial of Preoperative Chemotherapy for Biliary Tract Cancer (BTC) With Node Metastasis

25 enrolled

Biliary Tract Neoplasms

NCT03825328 2019-01-31

A Trial of NS/GEMOX Chemotherapy in Patients With Untreated Pancreatic Cancer ( HZ-NS/GEMOX-PC )

Pancreatic Neoplasms

NCT03815461 2019-01-25

Nab-paclitaxel Combined With S-1 as Induction Therapy for Locally Advanced Pancreatic Cancer

60 enrolled

Locally Advanced Pancreatic Cancer

NCT03718624 2018-10-31

A Study of Intraperitoneal and Intravenous Paclitaxel Plus Apatinib and S-1 Conversion Therapy for Gastric Cancer With Positive Exfoliative Cancer Cells

36 enrolled

Gastric Cancer With Positive Exfoliative Cancer Cells

NCT03662035 2018-09-19

ASPC

Advanced Pancreatic Cancer

NCT03636308 2018-08-17

ASAGPAC

40 enrolled

Pancreatic Neoplasms

NCT03567629 2018-06-26

Evaluate the Efficacy of Irinotecan Versus Oxaliplatin in the First-line Treatment of Refractory Metastatic Colorectal Cancer

130 enrolled

mCRC

NCT03316326 2017-10-20

S-1, Irinotecan, and Oxaliplatin in Locally-Advanced Pancreatic Cancer

35 enrolled

Pancreatic Ductal Adenocarcinoma

NCT02618356 2017-10-02

Combined Use of Raltitrexed and S-1 as Treatment for Patients With Metastasizing Colorectal Cancer

82 enrolled